Novo Nordisk, type 2 diabetes
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups,
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
11don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Hosted on MSN6d
European Countries Are Cracking Down on Weight-Loss Drugs Like Wegovy—Could the U.S. Follow?Novo Nordisk, the pharmaceutical company behind the world’s most popular weight-loss injections, is expanding its global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback